Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Leveraging on Nan Fung Group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations and investors in the life science space. Through direct investments via Pivotal BioVenture Partners funds (both in the US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices and diagnostics) and across different development stages, Nan Fung Life Sciences has significant presence in both the US and Greater China.
Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences, is a venture capital firm specializing in venture building in the life sciences industry. Pivotal China closed on $150 million for its first fund and is setting up an additional $50 million equivalent RMB fund. Its investment strategy is centered on identifying promising innovative products and technologies and bringing them to build new companies in China. The Pivotal team includes experienced life science investors and entrepreneurs with a track record of venture building and scientific acumen.
Morningside Venture Capital was founded in Boston, USA in 1986 by the Chen family of Hong Kong. The Chen family founded Hang Lung Group in Hong Kong in 1960. Since its inception, Morningside Ventures has been paying attention to and attaching importance to the cutting-edge developments of the global biomedicine and healthcare business. Its companies operating and investing in this field are located in North America, Europe and Asia. Since 1992, Morningside Ventures has also begun to set foot in the Chinese mainland market, actively carrying out early investments in innovative technologies and disruptive medical technology and medical service models. The company has gathered a group of investors with deep industry technical background and venture capital management experience. So far, Morningside Ventures has invested in more than 100 early-stage medical-related projects in China.